Shares of ARS Pharmaceuticals Fall After no New Commercial Insurers Add Neffy

Dow Jones06-25

Shares of ARS Pharmaceuticals fell after the company said no commercial insurers had added its neffy nasal spray to their plans in the current insurance cycle.

Shares plunged 23% to $8.12 in after-hours trading Wednesday. The stock closed up 2.5% at $10.54, down 9.5% this year.

The company highlighted that neffy was added to Florida state Medicare coverage, but said there had been no commercial formulary additions or coverage decisions despite discussions with some payers stretching into mid-June.

"ARS Pharma intends to continue working with the remaining payers, and notes that neffy remains broadly accessible to commercially insured patients with the combination of direct coverage and a recently introduced retail cash option at a price consistent with other epinephrine products, the company said. "Demand has continued to grow independent of additional coverage additions."

The company cut its planned full-year cash-based operating expenses to around $248 million, citing cost discipline and the prioritization of commercial investments. It reaffirmed its outlook of reaching cashflow breakeven in 2027.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

June 24, 2026 18:25 ET (22:25 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646841288?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646841288","market":"sh","top_or_hot":-1,"title":"Shares of ARS Pharmaceuticals Fall After no New Commercial Insurers Add Neffy","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ARS Pharmaceuticals fell after the company said no commercial insurers had added its neffy nasal spray to their plans in the current insurance cycle. \n</p>\n<p>\n  Shares plunged 23% to $8.12 in after-hours trading Wednesday. The stock closed up 2.5% at $10.54, down 9.5% this year. \n</p>\n<p>\n  The company highlighted that neffy was added to Florida state Medicare coverage, but said there had been no commercial formulary additions or coverage decisions despite discussions with some payers stretching into mid-June. \n</p>\n<p>\n  \"ARS Pharma intends to continue working with the remaining payers, and notes that neffy remains broadly accessible to commercially insured patients with the combination of direct coverage and a recently introduced retail cash option at a price consistent with other epinephrine products, the company said. \"Demand has continued to grow independent of additional coverage additions.\" \n</p>\n<p>\n  The company cut its planned full-year cash-based operating expenses to around $248 million, citing cost discipline and the prioritization of commercial investments. It reaffirmed its outlook of reaching cashflow breakeven in 2027. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 24, 2026 18:25 ET (22:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shares of ARS Pharmaceuticals Fall After no New Commercial Insurers Add Neffy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShares of ARS Pharmaceuticals Fall After no New Commercial Insurers Add Neffy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-25 06:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ARS Pharmaceuticals fell after the company said no commercial insurers had added its neffy nasal spray to their plans in the current insurance cycle. \n</p>\n<p>\n  Shares plunged 23% to $8.12 in after-hours trading Wednesday. The stock closed up 2.5% at $10.54, down 9.5% this year. \n</p>\n<p>\n  The company highlighted that neffy was added to Florida state Medicare coverage, but said there had been no commercial formulary additions or coverage decisions despite discussions with some payers stretching into mid-June. \n</p>\n<p>\n  \"ARS Pharma intends to continue working with the remaining payers, and notes that neffy remains broadly accessible to commercially insured patients with the combination of direct coverage and a recently introduced retail cash option at a price consistent with other epinephrine products, the company said. \"Demand has continued to grow independent of additional coverage additions.\" \n</p>\n<p>\n  The company cut its planned full-year cash-based operating expenses to around $248 million, citing cost discipline and the prioritization of commercial investments. It reaffirmed its outlook of reaching cashflow breakeven in 2027. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 24, 2026 18:25 ET (22:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2646841288","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646841288","pubTimestamp":1782339900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ARS Pharmaceuticals fell after the company said no commercial insurers had added its neffy nasal spray to their plans in the current insurance cycle.Shares plunged 23% to $8.12 in after-hours trading Wednesday. The stock closed up 2.5% at $10.54, down 9.5% this year.The company highlighted that neffy was added to Florida state Medicare coverage, but said there had been no commercial formulary additions or coverage decisions despite discussions with some payers stretching into mid-June.\"ARS Pharma intends to continue working with the remaining payers, and notes that neffy remains broadly accessible to commercially insured patients with the combination of direct coverage and a recently introduced retail cash option at a price consistent with other epinephrine products, the company said. \"Demand has continued to grow independent of additional coverage additions.\"The company cut its planned full-year cash-based operating expenses to around $248 million, citing cost discipline and","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SPRY":"ARS PHARMACEUTICALS INC"},"translate_title":"由于没有新的商业保险公司加入Neffy，ARS Pharmaceuticals股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":0.9},"content_text":"Shares of ARS Pharmaceuticals fell after the company said no commercial insurers had added its neffy nasal spray to their plans in the current insurance cycle. \n\n\n  Shares plunged 23% to $8.12 in after-hours trading Wednesday. The stock closed up 2.5% at $10.54, down 9.5% this year. \n\n\n  The company highlighted that neffy was added to Florida state Medicare coverage, but said there had been no commercial formulary additions or coverage decisions despite discussions with some payers stretching into mid-June. \n\n\n  \"ARS Pharma intends to continue working with the remaining payers, and notes that neffy remains broadly accessible to commercially insured patients with the combination of direct coverage and a recently introduced retail cash option at a price consistent with other epinephrine products, the company said. \"Demand has continued to grow independent of additional coverage additions.\" \n\n\n  The company cut its planned full-year cash-based operating expenses to around $248 million, citing cost discipline and the prioritization of commercial investments. It reaffirmed its outlook of reaching cashflow breakeven in 2027. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 24, 2026 18:25 ET (22:25 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646841288","isCrawlerRequest":true}